We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Noninvasive Hemoglobin Monitor Uses Occlusion Spectroscopy Technology

By LabMedica International staff writers
Posted on 30 Jun 2011
A noninvasive hemoglobin (Hb) monitor, which measures key blood parameters, reduces the risk of a technician's contact with donor blood. More...


The portable noninvasive device operates via a ring-shaped sensor that is fitted on the donor's finger. The device applies pressure, temporarily gently squeezing the finger to over-systolic pressure, similar to blood pressure measurements, thus occluding local blood flow. During the occlusion, optical elements in the sensor, using an array of calibrated light sources, measure absorption, and scattering of the light transmitted through the finger.

Called occlusion spectroscopy, the method provides a quick, accurate, and painless measurement of the donor's blood constituents, while improving the donor's comfort, reducing infection risk, and providing the medical staff with accurate readings and immediate results.

Developed by OrSense Ltd. (Nes Ziona, Israel) the new device will allow donors to undergo blood testing without the need for a finger prick. The noninvasive method will also increase donor and staff safety. The hemoglobin/hematocrit monitor was granted CE approval and was tested on over 8,000 patients and donors at more than 20 sites in the United States and Europe.

OrSense noninvasive Hb monitor performance was highlighted in a study presented during the Euroanesthesia 2011 conference of the European Society of Anesthesia, held in Amsterdam (The Netherlands) from June 11-14, 2011. The study, directed by Prof. P. Singer from the general ICU Rabin Medical Center (Petah Tiqva, Israel) and Aharon Weinstein from OrSense, showed that OrSense's device was able to track accurately rapid changes in Hb levels, and maintained reliability even at very low Hb blood content.

In a statement on World Blood Donors Day, Dr. Emma Castro, CEO of the Transfusion Center of the Spanish Red Cross (Madrid, Spain), said, "A noninvasive system for the measurement of predonation Hb is eagerly awaited by both donors and staff. Our donors are very excited about the implementation of the new OrSense system and we are looking at it as a tool that will contribute to enlarge our blood donor community."

The U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA) gave clearance for the OrSense noninvasive multiparameter monitor for continuous and spot measurement of normal and low signal oximetry for use in hospitals and outpatient sites. The company's CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors.

Related Links:
OrSense
European Society of Anesthesia
Rabin Medical Center


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.